Lts Lohmann Therapie-systeme Ag

Gruenenthal Gmbh

Grunenthal Gmbh

Regine Kaufmann

Patrick Mohr

René Eifler

Michael Horstmann

Marco Emgenbroich

Eric Galia

Nico Reum

Jan Stampfuss

Jessica Verstraelen

Wolfgang Prange

Stefan Buller

Klaus Pusecker

Susanne Stoelben

The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.

Transdermal therapeutic system for the transdermal administration of rivastigmine

The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Transdermal administration of memantine

The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Transdermal therapeutic system having controlled active substance flow comprising a basic reacting oxide

Growing community of inventors

Neuwied, Germany

Regine Kaufmann